Monthly Archives: June 2020

2014-2029 Report on Global Stem Cell Therapy Market By Player, Region, Type, Application And Sales Channel the new research report adds in kandjmarketresearch.com research reports database. Complete report On Stem Cell Therapy Research Report Spread Across 109 Pages, With Summarizing Top Companies and Stem Cell Therapy with Tables and Figures.

Market Overview

The global Stem Cell Therapy market has been studied by a set of researchers for a defined forecast period of 2014 to 2029. This study has provided insights to the stakeholders in the market landscape. It includes an in-depth analysis of various aspects of the market. These aspects include an overview section, with market segmentation, regional analysis, and competitive outlook of the global Stem Cell Therapy market for the forecast period. All these sections of the report have been analyzed in detail to arrive at accurate and credible conclusion of the future trajectory. This also includes an overview section that mentions the definition, classification, and primary applications of the product/service to provide larger context to the audience to this report.

Market Dynamics

The report on the global Stem Cell Therapy market includes a section that discusses various market dynamics that provide higher insight in the relationship and the impact of change these dynamics hold on the market functioning. These dynamics include the factors that are providing impetus to the market over the forthcoming years for growth and expansion. Alternatively, it also includes factors that are poised to challenge the market growth over the forecast period. These factors are expected to reveal certain hidden trends that aid in the better understanding of the market over the forecast period.

The Final Report Will Include the Impact of COVID 19 Analysis in This Stem Cell Therapy Industry.

Get Free Sample Report on Stem Cell Therapy @: https://www.kandjmarketresearch.com/sample-request/328640

Key Players

The global Stem Cell Therapy market report has provided a profiling of significant players that are impacting the trajectory of the market with their strategies for expansion and retaining of market share.

Leading players of Stem Cell Therapy including:

Market split by Type, can be divided into:

Market split by Application, can be divided into:

Do You Have Any Query or Specific Requirement? Ask to Our Trade Expert @ https://www.kandjmarketresearch.com/enquiry/328640

Market Segmentation

The global Stem Cell Therapy market has been studied for a detailed segmentation that is based on different aspects to provide insight in the functioning of the segmental market. This segmentation has enabled the researchers to study the relationship and impact of the growth chart witnessed by these singular segments on the comprehensive market growth rate. It has also enabled various stakeholders in the global Stem Cell Therapy market to gain insights and make accurate relevant decisions. A regional analysis of the market has been conducted that is studied for the segments of North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

Research Methodology

The global Stem Cell Therapy market has been analyzed using Porters Five Force Model to gain precise insight in the true potential of the market growth. Further, a SWOT analysis of the market has aided in the revealing of different opportunities for expansion that are inculcated in the market environment.

Market split by Sales Channel, can be divided into:

Market segment by Region/Country including:

Read More Detailed Information regarding Stem Cell Therapy Industry with Covid-19 Updates @: https://www.kandjmarketresearch.com/reports/328640-2014-2029-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel

About Us:

Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world. We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source.

If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

Contact us:

KandJ Market Research

(Part of KnowledgeNJournals Research)

E-mail: [emailprotected]

Website: https://www.kandjmarketresearch.com

Call us: +1 661 636 6162 | +91 932 580 2062

Read this article:
Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic - Jewish Life News

Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells

Italy, Milan, 30 June 2020: The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire, a gene therapy company developing transformative therapies for genetic diseases, announce today the publication of data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology.

The paper, entitled Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, outlines technology developed by Pr. Luigi Naldini and his team at SR-Tiget, which is included in the strategic alliance with Genespire. It shows increased homology directed recombination (HDR) efficiency in HSCs by forcing cell-cycle progression and transiently upregulating components of the HDR machinery. The findings are validated by clonal tracking of the edited HSCs in experimental transplantation models, which shows improved polyclonal engraftment by long-term repopulating HSCs.

People with genetic diseases affecting the hematopoietic lineage may benefit from corrective targeted gene therapy in HSCs. These cells are self renewing and can differentiate into all the cell types of the hematopoietic lineage, therefore providing the potential for a one-time therapy. As compared to standard gene replacement approaches, gene editing corrects the disease-causing mutation in situ, restoring both function and physiological expression control of the affected gene. In principle, this targeted strategy may fulfill the goal of precision medicine at the most stringent genetic level. Its realization in HSCs, however, has been hampered until now by low efficiency of HDR-driven repair, likely because of the quiescent state of the more primitive progenitors. Use of the improved gene editing technology developed by SR-Tiget has been shown to yield a greater percentage of gene-edited HSCs and increased clonality, or the number of modified cells transplanted and engrafted in the recipient. In a clinical setting this should lead to increased hematopoietic cells chimerism in the patient receiving the corrective HSC therapy, and could accelerate the hematopoietic recovery after conditioning and increase the size, long-term stability, and safety of the engineered cell graft.

This approach can be applied to genetic diseases originating in the hematopoietic lineage, including primary immune deficiencies (PIDs), a key area of focus for Genespire. Genespire will continue to work with SR-Tiget and apply this technology to its future pipeline of gene therapies.

Julia Berretta, Chief Executive Officer of Genespire, commented: The focus of Genespires alliance with SR-Tiget is to research and develop novel gene therapies, addressing severe diseases with high unmet medical need. We are pleased with the publication of these data in Nature Biotechnology, which provide valuable insights into this pioneering technology developed by SR-Tiget, and we look forward to our future work with them to translate cutting edge science into transformational therapies.

Professor Luigi Naldini, Director of SR-Tiget and scientific co-founder of Genespire, said Our findings elucidate and overcome two main biological barriers to efficient HDR-mediated gene editing in HSCs, and show by clonal tracking that our enhanced editing protocol preserves their multilineage and self-renewal capacity long term after serial transplant. We look forward to our future work with Genespire to explore its potential in primary immunodeficiencies.

The full publication details are below and can be accesed online here.

Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking Samuele Ferrari, Aurelien Jacob, Stefano Beretta, Giulia Unali, Luisa Albano, Valentina Vavassori, Davide Cittaro, Dejan Lazarevic, Chiara Brombin, Federica Cugnata, Anna Kajaste-Rudnitski, Ivan Merelli, Pietro Genovese and Luigi Naldini

Enquiries:

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini and Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About SR-Tiget

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

Read the rest here:
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in...

The global Stem Cell Banking Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Stem Cell Banking Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Stem Cell Banking Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Stem Cell Banking Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Stem Cell Banking Market.

Leading players of the global Stem Cell Banking Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Stem Cell Banking Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Stem Cell Banking Market. It also provides useful recommendations for new as well as established players of the global Stem Cell Banking Market.

Final Stem Cell Banking Report will add the analysis of the impact of COVID-19 on this Market.

Stem Cell Banking Market competition by top manufacturers/Key player Profiled:CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2149312

Stem Cell Banking refers to the human stem cell transplantation for the purpose, with acquisition, processing, preservation and provides the ability to differentiate stem cell storage bank, has been called the 'life bank'.The global Stem Cell Banking market size is estimated at xxx million USD with a CAGR xx% from 2015-2020 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Stem Cell Banking by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Segmentation by Product:Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Others

Segmentation by Application:Diseases Therapy, Healthcare

Competitive Analysis:

Global Stem Cell Banking Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cell Banking Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Stem Cell Banking Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

Key Questions Answered:

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2149312

Table of Contents

Report Overview:It includes major players of the global Stem Cell Banking Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Stem Cell Banking Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Stem Cell Banking Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Stem Cell Banking Market by application, it gives a study on the consumption in the global Stem Cell Banking Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Stem Cell Banking Market are profiled in this section. The analysts have provided information about their recent developments in the global Stem Cell Banking Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Stem Cell Banking Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Stem Cell Banking Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Stem Cell Banking Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See the rest here:
Global Covid-19 impact on Stem Cell Banking Market Trends, Analysis by Application and Region by 2025| CCBC,CBR,ViaCord,Esperite - 3rd Watch News

Global Stem Cell Assay Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the global Stem Cell Assay Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Stem Cell Assay Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a Global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Stem Cell Assay market between 2020 and 2027. In terms of value, the Stem Cell Assay industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1632

The key players profiled in this report include: Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Stem Cell Assay

o The micro-level analysis is conducted based on its product types, end-user applications, and geographie

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Stem Cell Assay market

Table of Contents

Report Overview: It includes the Stem Cell Assay market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Stem Cell Assay market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Stem Cell Assay market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Stem Cell Assay market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1632

The research study can answer the following Key questions:

Major Highlights of TOC:

Chapter One: Global Stem Cell Assay Market Industry Overview

1.1 Stem Cell Assay Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Stem Cell Assay Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Global Stem Cell Assay Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Stem Cell Assay Market Size by Demand

2.3 Global Stem Cell Assay Market Forecast by Demand

Chapter Three: Global Stem Cell Assay Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Stem Cell Assay Market Size by Type

3.3 Stem Cell Assay Market Forecast by Type

Chapter Four: Major Region of Stem Cell Assay Market

4.1 Global Stem Cell Assay Sales

4.2 Global Stem Cell Assay Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/1632

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

Follow this link:
Stem Cell Assay Market Future Trends and Forecast to 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad...

New Jersey, United States,- The latest research study on Stem Cell Banking Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Stem Cell Banking market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Stem Cell Banking Market was valued at USD 1.47 billion in 2016 and is projected to reach USD 7.52billion by 2025, growing at a CAGR of 19.89% from 2017 to 2025.

Download Sample Copy of Stem Cell Banking Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=23773&utm_source=APS&utm_medium=007

The research report on the Stem Cell Banking market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Stem Cell Banking market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Stem Cell Banking market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Stem Cell Banking market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Stem Cell Banking Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=23773&utm_source=APS&utm_medium=007

As per the regional scope of the Stem Cell Banking market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Banking-Market/?utm_source=APS&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Pyrogen Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Banking Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cell Expansion Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wearable Skin Patch Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Fetal Monitoring Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more here:
Stem Cell Banking Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Apsters News

The decision comes almost exactly a month after results from KEYNOTE-177 were presented at the annual meeting of the American Society of Clinical Oncology.

Merck, which makes pembrolizumab, sold as Keytruda, announced the approval in a statement.

The approval covers patients who have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and is based on results of KEYNOTE-177, a phase 3 trial of 307 patients that found the programmed cell death-1 (PD-1) inhibitor trimmed the risk of death of disease progression 40% compared with chemotherapy, which is the current standard of care (HR = 0.60, 95% CI: 0.45-0.80, P = .0004).

Results presented at ASCO showed that pembrolizumab doubled progression-free survival in these colorectal cancer patients, from 8.2 months to 16.5 months. Lead study author Thierry Andr MD, of the Sorbonne Universit and Hpital Saint Antoine in Paris, said at the time that the findings would change the standard of care. No medical treatment has shown such an improvement, Andr said.

Discussant Michael Overman, MD, of The University of Texas MD Anderson Cancer Center, agreed and said the tumors treated in the study were particularly good candidates for immunotherapy. From now on, he said, It is critical that we test all colorectal cancer patients for mismatch repair or microsatellite status.

The approval came less than a month after Merck submitted a supplemental Biologics License Application, which was handled through FDAs Real-Time Oncology Review pilot program. According to the Merck statement, the approval was reviewed under Project Orbis, an initiative of the FDA Oncology Center of Excellence that allows for concurrent submission and review of oncology drugs among its international partnersin this case, regulators in Australia, Canada, and Switzerland.

Todays approval has the potential to change the treatment paradigm for the first-line treatment of patients with MSI-H colorectal cancer, based on the important findings from KEYNOTE-177 that showed Keytruda monotherapy demonstrated superior progression-free survival compared to standard of care chemotherapy, Roy Baynes, MD, PhD, senior vice president and head of global clinical development, chief medical officer for Merck Research Laboratories, said in the statement.

At ASCO, Andr trumpeted the value of biomarker-driven research, and Baynes did the same today. Our commitment to pursuing biomarker research continues to help us bring new treatments to patients, he said, particularly for those who have few available options.

Immune-related adverse events can include pneumonitis, colitis, hepatitis, skin reactions, renal dysfunction, and endocrinological abnormalities. Patients taking the PD-1 inhibitor may experience solid organ transplant rejection or complications from stem cell transplant.

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center. said in the statement that patients with colorectal cancer and the genetic mutations in the study have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options.

About 5% of metastatic colorectal cancer patients have MSI-H/dMMR. Pembrolizumabs effectiveness when this mutation is present is well-recognized, and led to FDAs firsttissue-agnostic approvalin May 2017.

See more here:
Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations - AJMC.com Managed Markets Network

The Global Autologous Stem Cell Transplantation Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost, and revenue during the forecast period from 2020 to 2027. The report provides a full assessment. Autologous Stem Cell Transplantation market with future trends, current growth factors, meticulous opinions, facts, historical data and statistically supported and industry-validated market data.

This Autologous Stem Cell Transplantation market research provides a clear explanation of how this market will impress growth during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

To Learn More About This Report, Request a Sample Copy:https://www.worldwidemarketreports.com/sample/285423* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

ANTRIA (CRO), BIOHEART, BRAINSTORM CELL THERAPEUTICS, CYTORI, DENDREON CORPORATION, FIBROCELL, GENESIS BIOPHARMA, GEORGIA HEALTH SCIENCES UNIVERSITY, NEOSTEM, OPEXA THERAPEUTICS, ORGENESIS, REGENEXX, REGENEUS, TENGION, TIGENIX, VIRXSYS are some of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

Key players in the Autologous Stem Cell Transplantation market were identified through a second survey, and their market share was determined through a primary and second survey. All measurement sharing, splitting, and analysis were solved using a secondary source and a validated primary source. The Autologous Stem Cell Transplantation market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure, and when used together, how key players can meet market coverage, offered characteristics, and customer needs It helps to understand.

The report also makes some important suggestions for new Autologous Stem Cell Transplantation market projects before evaluating their feasibility. Overall, this report covers Autologous Stem Cell Transplantation market Sales, Price, Sales, Gross Profit, Historical Growth,and Future Prospects. It provides facts related to the widespread merger, acquisition, partnership, and joint venture activities on the market.

This report includes market size estimates of value (million US $) and trading volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Autologous Stem Cell Transplantation market, estimating the size of various other subordinate markets in the overall market. All ratio sharing, splitting, and analysis were determined using the secondary source and the identified primary source.

What Autologous Stem Cell Transplantation Market report offers:

Remarkable Attributes of Autologous Stem Cell Transplantation Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Read more:
Autologous Stem Cell Transplantation Market 2020 | Incredible Possibilities, Growth With Detailed Analysis and Forecast to 2027: ANTRIA (CRO),...

Michael Schumacher is still surviving as he continues to battle complications from the near-fatal head injury he sustained while skiing in 2013. It was reported that the F1 legend is set to undergo another round of stem cell procedure that will help regenerate his nervous system.

Facts about the reported new operation on Schumi

With this surgery, his family and doctors are hoping that he will be able to recover functions in parts of his body. This is because it is aimed at his sensory system that was affected by his injuries.

The Daily Mail reported that currently, Michael Schumacher is being treated and cared for by French cardiologist Dr. Philippe Menasche, a medical expert specializing in stem cell research. It was revealed that a series of surgeries are needed for this treatment, so this is just one of the racing champs operations for his recovery.

In an article that appeared in an Italian publication Le Dauphine, it was reported that Dr. Menasche will do seminal heart surgery on Schumi in his next surgery schedule. It was added that this will take place soon, but the exact date was not revealed.

It is also believed that this will be the second time that the said doctor is operating on Michael Schumacher. The first procedure was said to have been done in September 2019, and Schumi was in the hospital for about three days. At any rate, in this operation, his damaged cells will be replaced with healthy ones that will be taken from his bone marrow.

An experimental stem-cell surgery?

Michael Schumacher has not recovered from his accident that happened more than six years ago. He is currently being treated in his own home in Switzerland, but his exact condition is still a mystery since his family continues to keep everything related to his health a secret.

Dr. Nicola Acciari, a leading neurosurgeon, previously claimed that Michael Schumacher has osteoporosis and suffering from muscle atrophy since he is unable to move for years. The goal is to regenerate Michaels nervous system, The Sun quoted him as saying in connection to the stem cell therapy.

However, Jean-Michel Dcugis, a French journalist, shared to British daily national newspaper, The Times, that the procedure is experimental at this point since Dr. Menasche is actually a cardiologist.

"Our sources say that Michael Schumacher is receiving stem cell perfusions that produce a systemic anti-inflammatory effect, The Sun quoted Dcugis as saying. "It's quite mysterious as Menasch works only on the heart. He is carrying out experiments with secretome that is made by a laboratory from new stem cells and injected into veins, until now only on animals.

Read more from the original source:
Michael Schumacher is reportedly getting another stem-cell surgery; Journalist alleged it will be an experimental procedure - EconoTimes

A report on Stem Cell Therapy market compiled by Brand Essence Market Research provides a succinct analysis regarding the values and trends existing in the current business scenario. The study also offers a brief summary of market valuation, market size, regional outlook and profit estimations of the industry. Furthermore, the report examines the competitive sphere and growth strategies of leading players in the Stem Cell Therapy market.

In 2018, the GlobalStem Cell Therapy Marketsize was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Download Premium Sample of the Report:https://industrystatsreport.com/Request/Sample?ResearchPostId=595&RequestType=Sample

Key playersof the Stem Cell Therapy market are Gilead, Novartis, Organogenesis, Vericel, Others

Stem Cell Therapy Market Segmentation:

Reports include the following segmentation: By Product TypeAdult Stem CellsHuman Embryonic Stem Cells (hESC)Induced Pluripotent Stem CellsVery Small Embryonic Like Stem CellsBy Applications TypeRegenerative MedicineDrug Discovery and DevelopmentBy TechnologyCell AcquisitionCell ProductionCryopreservationExpansion and Sub-CultureBy Cell TherapyAutologousAllogeneicBy RegionNorth Americao U.S.o Canadao MexicoEuropeo UKo Franceo Germanyo Russiao Rest of EuropeAsia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-PacificLAMEAo Latin Americao Middle Easto Africa

Region Coverage (Regional Production, Demand & Forecast by Countries etc.):North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)Middle East & Africa (Saudi Arabia, South Africa etc.)

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Stem Cell Therapy Market Size Growth Rate by Type (2014-2025)1.4.2 Topical Products1.4.3 Botulinum1.4.4 Dermal Fillers1.4.5 Chemical Peels1.4.6 Microabrasion Equipment1.4.7 Laser Surfacing Treatments1.5 Market by Application1.5.1 Global Stem Cell Therapy Market Share by Application (2014-2025)1.5.2 Hospitals1.5.3 Dermatology Clinics1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Stem Cell Therapy Market Size2.2 Stem Cell Therapy Growth Trends by Regions2.2.1 Stem Cell Therapy Market Size by Regions (2014-2025)2.2.2 Stem Cell Therapy Market Share by Regions (2014-2019)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities

3 Market Share by Key Players3.1 Stem Cell Therapy Market Size by Manufacturers3.1.1 Global Stem Cell Therapy Revenue by Manufacturers (2014-2019)3.1.2 Global Stem Cell Therapy Revenue Market Share by Manufacturers (2014-2019)3.1.3 Global Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.2 Stem Cell Therapy Key Players Head office and Area Served3.3 Key Players Stem Cell Therapy Product/Solution/Service3.4 Date of Enter into Stem Cell Therapy Market3.5 Mergers & Acquisitions, Expansion Plans

Read More:https://industrystatsreport.com/Semiconductor-and-Electronics/Stem-Cell-Therapy-Market-Share/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at[emailprotected]

View original post here:
Stem Cell Therapy Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2020 2025 - Owned

GOLDEN, COLO / ACCESSWIRE / June 29, 2020 / Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30th 2020 financial results of operations.

Vitro Diagnostics Inc. ("Vitro Biopharma") announced a reduction in 2nd quarter revenues across all its revenue categories. Vitro Biopharma recorded 2nd quarter revenues of $128,631 vs $211,900 a decrease of 39% over the same comparative quarter last year. Prior to the lockdowns which began at different times for different jurisdictions Vitro had reported increasing revenues across all its revenue categories for 13 consecutive quarters. We expect to see revenue returning in the 4th quarter of 2020 and into the first half of 2021. Preliminary feedback from our customers indicates that patients awaiting treatments at our partner clinic in the Cayman Islands http://www.DVCstem.com are not dropping off but merely postponing their treatments and as such a backlog is building rather than customer cancellations. The cosmetic clinics http://www.Infinivive.com have started to open up but only with reduced occupancy and variations by state and hence reduced revenue into the 3rd quarter with expectations of a revival of revenue in the 4th quarter of 2020 and into the first half of 2021.

Overall operating expenses increased in the quarter by $114,178 to $281,485 from $167,307 in the prior year's comparative quarter. The increase in expenses reflects the increased costs of FDA regulatory, legal, consulting, business and product development expenses. The company added extra resources to turn its attention to the world wide challenge of finding therapies to fight the Covid-19. Vitro filed an Investigational New Drug ("IND") application and also received emergency use authorization from the FDA for use of AlloRx Stem Cells ® in the treatment of COVID-19 patients. A patient was treated subsequent to the end of the second quarter. There were no adverse events demonstrating safety and the patient showed evidence of efficacy including improved lung and kidney function. We also entered into an MOU with GIOSTAR, a leading global stem cell research operating multiple international stem cell clinics.

During and subsequent to the quarter the company achieved and pursed the following objectives:

During the quarter and subsequent to the quarter the company continued with its Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $550,000 of the Series A Convertible Preferred Stock during and subsequent to the quarter. The offering was sold out at $1,000,000 and the company is considering expanding it to ensure sufficient working capital during the Coronavirus pandemic and to start the regulatory process of current reporting audits and funding for its expanded clinical trial activities with the FDA.

As a part of our overall strategy to target both global and US stem cell markets, Vitro submitted a Phase I IND application to the FDA https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/) to assess safety of AlloRx Stem Cells® in the treatment of COVID-19 patients in the US. Recent umbilical cord stem cell therapies in China to fight the Coronavirus has produced encouraging safety and efficacy results. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells®. The application is presently under review and we are working closely with FDA reviewers to gain authorization to enroll patients. Several clinical centers have expressed interest in our stem cell therapy. We are also pursuing other avenues for Emergency Use Authorization (EUA). The FDA has thus far authorized three separate EUA applications for compassionate use of AlloRx Stem Cells® in COVID-19 patients. Unfortunately, two patients died prior to treatment. A single patient has been treated by three separate dosages of AlloRx Stem Cells® through an authorized EUA by GIOSTAR. There were no adverse events and the patient who has various comorbidities stabilized and exhibited enhanced pulmonary and renal functions during the six weeks following AlloRx Stem Cell® Therapy. While presently intubated and hospitalized in the ICU, this patient is exhibiting gradual improvement. We are presently pursuing additional EUA applications through our collaboration with GIOSTAR https://vitrobiopharma.com/vitro-biopharma-signs-mou-with-GIOSTAR-for-covid-19-ind-using-allorx-stem-cells/. The data obtained from these studies corroborates our studies of safety and efficacy. Mesenchymal Stem Cells ("MSCs") block the cytokine storm that occurs in COVID-19 patients in acute respiratory distress through their powerful anti-inflammatory effects. The cytokine storm leads to the need for assisted breathing by ventilators, transfer to ICU and tremendous burdens on the US health care system. It is important to note that AlloRx Stem Cells® are therapy for other viral attacks including influenza since stem cells block acute respiratory distress and damage to other major organs including cardiovascular, pulmonary and renal systems. AlloRx Stem Cells® are very likely to assist in recovery from failure of various organ systems in COVID-19 survivors, as our case study is demonstrating.

We entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. ("GIOSTAR") a leading stem cell research institute based in San Diego, California to jointly partner together for a separate COVID-19 Investigational New Drug ("IND") application to the FDA using Vitro Biopharma's umbilical cord MSC product AlloRx Stem Cells in a clinical trial to treat Covid-19 patients https://vitrobiopharma.com/vitro-biopharma-signs-mou-with-GIOSTAR-for-covid-19-ind-using-allorx-stem-cells/ GIOSTAR is a worldwide leader in the in the field of stem cell research and has stem cell research and treatment facilities around the world. GIOSTAR is leading the way for filling the joint IND application for a Covid-19 trial with the FDA while Vitro will provide its AlloRx Stem Cells® for use in the study and post-approval stages through a supply agreement with GIOSTAR. GIOSTAR has already obtained EUAs from the FDA for using stem cell treatment for severe Covid-19 hospitalized patients using AlloRx Stem Cells®. https://www.GIOSTAR.com/2020/05/01/GIOSTAR-announces-fda-approval-compassionate-use-treat-covid-19-stem-cells-2/

Vitro will continue to seek FDA authorization of its pending IND. As the approval process proceeds, Vitro will seek AlloRx Stem Cells® FDA approval through Phase 2/3 IND filings for indications other than COVID-19 such as osteoarthritis while at the same time continuing to supply GIOSTAR AlloRx Stem Cells® for treatment of COVID-19 patients in global markets.

GIOSTAR in collaboration with government of Gujarat, India is building one of the world's largest stem cell hospitals. This is a dream project of India's Prime Minister Narendra Modi. The MOU stated the intended discussions regarding the use of AlloRx Stem Cells® at GIOSTAR's various international stem cell facilities that would provide quality and economic advantages.

The company is doubling its laboratory and manufacturing facilities and expanding its clean room by 100% in size and capacity. This new facility is expected to be online during the 1st quarter of next year. This represents approximately $6M of AlloRx Stem Cell Vitro Biopharma revenue capacity per year. Furthermore, the completion of the 2nd clean room processing facility at the beginning of the 2021 year will expand our capacity to approximately 100 Billion AlloRx Stem Cell s a month or approximately $1.7 Million of AlloRx Stem Cell Vitro Biopharma revenue capacity per month. This would give Vitro Biopharma a revenue run rate capacity of $20M a year.

Our increased capacity is rigorously controlled by our Quality Management System, now certified to the ISO9001 Quality and the ISO13485 Medical Device Standards as well. This provides GMP-compliant manufacturing of the highest quality stem cells/medical devices for clinical trial testing to provide further evidence of safety and efficacy for treatment of a wide variety of indications. Highly regulated GMP biologics manufacturing within an FDA-compliant facility provides numerous opportunities to the Company to drive strong revenue growth. We are presently focused on our partnerships in the Caribbean with DVC Stem in Grand Cayman Island, Infinivive MD in the US and emerging opportunities in the Commonwealth of the Bahamas. We are actively pursuing other partnership opportunities as well.

We have reformulated with our Contract Manufacture to produce STEMulize in large quantity manufacturing runs. STEMulize contains natural substances that activate the body's own stem cells to enhance recovery from injury such as TBI, stroke, MS, PD and other autoimmune, inflammatory and neurological diseases. The STEMulize product will be offered as a private label product to Infinivive MD clinics and is being implemented as supplemental support to clinical treatments now ongoing in the Cayman Islands. Patients report positive benefits from STEMulize therapy following stem cell transplants including increased overall energy and enhancement of improved motor function in MS patients. We are currently pursing licensing arrangements with nutraceutical companies that can scale our formulation under their own private label.

The Company's cosmetic stem cell serum private labelled as Infinivive MD Serum is being applied as a topical cosmetic serum in medical spas and plastic surgery offices. Infinivive MD revenue was reduced by the Coronavirus pandemic and as a result, revenues declined by 50% in the quarter to approximately $50,000 vs $100,000 in the prior quarter. This also compares to $50,000 in the current quarter of 2020 vs $130,000 in the prior comparative quarter of 2019.

The Joint Development and Supply Agreement dated May 15th 2018 between Vitro Biopharma and Jack Zamora is being renegotiated due to the Coronavirus pandemic and as such the minimum exclusivity requirements have been delayed by approximately a year.

Infinivive MD Cosmetic Serum is revolutionizing the cosmetic industry. Patients are experiencing unparalleled improvements in the appearance of fine lines and wrinkles. This is one of the fastest growing revenue streams for Vitro Biopharma. We work with a variety of regulatory experts to assist us in the appropriate regulatory pathway. At this point it is regulated as a cosmetic topical product but may be reclassified based on regulatory input.

http://www.jackzamoramd.comwww.infinivivemd.com

Infinivive MD also has an exclusive agreement to distribute AlloRx Stem Cells into the countries of Saudi Arabia, U.A.E., and Colombia. A trial was conducted in Kuwait prior to the pandemic and upon reopening of the country the first commercial orders will be shipped. The agreement calls for minimum commitments to maintain exclusivity and provides for minimum revenue of $250,000 annually in 2020. However due to the worldwide Corona Virus lockdown of business and customers the agreement for performance requirements have been delayed by approximately a year.

Vitro Biopharma's OEM cosmetic topical serum is being distributed exclusively by Infinivive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in a number of clinics throughout the United States and soon internationally; but with the clinics just opening again for business and with limited occupancy rules we do not expect this revenue to recover back to peak levels with growth until the first half of 2021.

Update on the Clinical Trial of Musculoskeletal Conditions in the Bahamas

This initiative broadens Vitro Biopharma's expansion into highly regulated stem cell trials in collaboration with the Nassau-based Medical Pavilion of the Bahamas (TMPB).

Home

We will now be able to extend stem cell therapy based on our novel, patent-pending AlloRx Stem Cell product to a variety of musculoskeletal conditions. These include OA of any joint, ACL/MCL tear, Achilles tendon rupture, rotator cuff injury, tennis elbow and herniated disc that are highly prevalent and have few disease-modifying options. It is important to note that many stem cell treatments now performed are problematic due to limited potency and failure to meet basic qualification criteria of MSC stem cells.. Also, contamination due to poor production methods that are not in compliance with FDA regulations has caused serious complications, resulting in FDA warning letters due to manufacturing infractions. Vitro Biopharma operates a highly regulated, FDA-compliant commercial biologics manufacturing operation for several years and is cGMP compliant, ISO 9001 Certified, ISO 13485 Certified, CLIA Certified and FDA registered. All manufacturing occurs in a certified sterile clean room with extensive and advanced testing to assure the absence of contamination. Furthermore, in numerous patients treated to date by IV infusion of AlloRx Stem Cells there have been no significant adverse events.''

The company is partnered with Dr. Conville Brown, MD, MBBS, FACC, FESC, PhD, the founder and CEO of the Medical Pavilion of the Bahamas who is the Principal Investigator of this trial and director of its clinical administration. Dr Brown was instrumental in the establishment of the National Stem Cell Ethics Committee in the Bahamas.

About the Medical Pavilion of the Bahamas: TMPB operates within a 40,000 square foot building as a partnered care specialty medical facility with 10 different centers in various areas including cardiology, cancer, clinical research and kidney disease. One of the centers is the Partners Stem Cell Centre, where the present trial will be conducted. The Partners Stem Cell Centre provides an environment to conduct stem cell research and clinical trials under the model of ''FDA rigor in a Non-FDA Jurisdiction'' TMPB employs 20 medical specialists in various fields. See http://www.tmp-bahamas.com for additional information.

The company expects to begin patient enrollment for the clinical trial in late QIV but does not expect to realize revenue until QI/QII of 2021.

Due to the Corona virus pandemic the Cayman Islands closed itself and its businesses down for the majority of the quarter and next quarter, the current status is listed as locked down until Sept. 1st 2020. However, our partner reports that customers are staying on the waiting list and will return for their treatments as soon as the island opens back up. There currently is a backlog of patients of over 40 treatments pending which exceeds all of the treatments performed in 2019. We expect to see a surge in revenues from this backlog to bring back our revenue stream in the fourth quarter of 2020 and into the first half of 2021.

The Company has several patent applications (11) pending in the US and foreign jurisdictions. These patents cover our AlloRx Stem Cell line and various aspects of our STEMulize stem cell activation products & processes as well as specific diagnostic tests of stem cell activity and therapeutic effectiveness. During the quarter, the Company has responded to office actions and continues to vigorously prosecute & expand its patent filings.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are pleased to report our activities in fighting the Covid-19 with filings of our eIND and INDs and partnership with GIOSTAR. While we are disappointed in the extraordinary impact of the Corona Virus pandemic and its results on our operations, we have taken the time to advance our clinical applications and partnerships in further preparation for realized growth in 2021 as a result of these activities.

Our stem cell products are distinctly superior to stem cell transplants in the USA. The latter usually involve use of impure products lacking validation as stem cells and containing insufficient numbers of stem cells to achieve therapeutic benefits. These are produced without regulatory oversight and have been known to cause serious adverse effects. Hence the use of highly purified and well characterized stem cells (AlloRx Stem Cells) is needed to provide safety and efficacy in regenerative medicine therapies.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10+ years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We plan to leverage our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Vitro Biopharma has supplied major biopharmaceutical firms, elite university laboratories and clinical trials worldwide with its Umbilical Cord Mesenchymal Stem Cells (AlloRx Stem Cells), and it's MSC-Grow Brand of cell culture media along with advanced stem cell diagnostic services. http://www.vitrobiopharma.com

Sincerely yours,

James R. Musick, PhD. President, CEO & Chairman of the Board http://www.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward- looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick Chief Executive Officer Vitro BioPharma (303) 999-2130 Ext. 3 E-mail: jim@vitrobiopharma.com http://www.vitrobiopharma.com

Vitro Diagnostics, Inc.

Quarter Ended April 30th;

Income Statement

Stem Cell Therapies and Treatments

Stem Cell Products

Other Services

Total Revenues

COGS

Gross Profit

SGA Expenses

Office Expenses

Consulting,Accounting,Legal and Banking Fees

Laboratory R&D & Quality Control

Total Operating Expenses

Net Operating Profit (Loss) EBITDA

Non Cash Depreciation and Amortization

Non Cash Stock for Services

Non Cash Interest on Shareholder Debt

Non Cash Interest on Secured Notes Payable

Net Income (Loss)

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnositics Inc.

Quarter Ended April 30th;

Balance Sheet

ASSETS

Cash

Accounts Receivable

Inventory

Notes Receivable and Prepaids

Current Assets

Fixed Assets

Intangible and other Assets

Total Assets

LIABILITIES

Trade Accounts Payable

Bank Credit Cards

Capital Lease Obligaitons

Current Liabiities

Secured Convertible Notes

Capital Lease Obligations

Shareholder Accrued Comp. Payable

Shareholder Debts Payable

Long Term Liabilities

Total Liabilities

SHAREHOLDERS EQUITY

Series A Convertible Preferred Stock

Common Stock

Paid in Capital

Retained Earnings

Net Income

Total Equity

TOTAL LIABILITES AND EQUITY

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnostics, Inc.

Quarter Ended April 30th;

Statement of Cashflows

Net Loss ended April 30th;

Non Cash Depreciation and Amortization

Increase in current and other Assets

Increase in Current and other Current Liabilities

Equipment,Patent and other capital Expenditures

Net cash used in operations during the Quarter

Cashflows from Financing Activities during the Quarter

See original here:
Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse